NEW YORK, May 30 - Sangamo Biosciences said Wednesday it has obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million.

Sangamo, which is currently completing due diligence, has until July 14 to exercise its option to acquire Gendaq, a London-based developer of zinc finger DNA binding proteins for gene regulating gene expression. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.